Aviado · Research
Longevity Daily
Monday, November 2, 2026
Listen
Today's Brief
Today's digest leads with a remarkable personal account: at 58, a patient reversed early Alzheimer's biomarkers through targeted lifestyle and medical intervention—evidence that up to 45% of dementia cases are preventable. Scientists also identify 'youthful' brain cells that help some people resist Alzheimer's despite carrying its hallmarks, opening a striking new therapeutic target. A 26-trial systematic review delivers a hard finding: lower epigenetic age scores don't reliably translate to better health outcomes. And Aviado unpacks CoQ10's second role as a ferroptosis blocker—a protection mechanism that matters more as natural production declines with age.
10 stories1 Aviado original
Cognitive Health & Neuroprotection
At 58, She Found Early Alzheimer's Biomarkers in Her Brain—Then Got Rid of Them
A first-person account from a 58-year-old who discovered amyloid and tau accumulation through imaging—and then systematically reversed those markers through a personalized protocol of diet, exercise, sleep, and medical intervention. Her story is anchored by growing evidence that up to 45% of dementia cases could be delayed or prevented by targeting modifiable risk factors like obesity, high cholesterol, and social isolation. This isn't anecdote: she documents before-and-after scans and the specific steps taken under clinical guidance. If cognitive decline is anywhere on your radar, this is the most actionable piece you'll read this week.
Read more →Some Brains Carry Alzheimer's Hallmarks but Stay Sharp—Scientists Now Know Why
Scientists have identified a population of 'youthful' brain cells that appear to preserve cognitive function even in people whose brains carry the amyloid plaques and tau tangles of Alzheimer's disease. The finding suggests that cognitive resilience is an active biological process driven by specific cell types—not just luck—and opens a new therapeutic angle: boosting the cells that can resist pathology, rather than solely clearing plaques. This reframes one of the most urgent questions in brain aging research.
Read more →Reading for Pleasure Is Linked to Better Brain Health Across Your Entire Lifespan
Cambridge University's Barbara Sahakian synthesized literacy surveys, long-term cohort studies, and brain imaging research to build a comprehensive case that recreational reading protects brain health from childhood through old age. The protective effects span cognitive reserve development in youth and appear to extend to reduced neurodegeneration risk in late life. Consider this science-backed permission to put down your phone and pick up a book.
Read more →Supplements & Compounds
CoQ10's Hidden Second Job: Blocking the Iron-Driven Cell Death That Damages Your Heart and Brain
Most people know CoQ10 as a mitochondrial energy booster—but new research reveals it simultaneously blocks ferroptosis, an iron-driven form of cell death that destroys organs through lipid oxidation. This dual action helps explain why CoQ10 supplementation consistently delivers clinical benefits in trials, and why its age-related production decline leaves energy-hungry tissues doubly vulnerable. For practical application, 100–150 mg daily of ubiquinol or ubiquinone with food is the evidence-supported protocol, with energy and skin improvements typically seen within 8–12 weeks. The ferroptosis-protection story is still emerging from lab data, but the mitochondrial benefits in humans are firmly established.
Read the full Aviado analysis →Metformin's Hidden Cost: Why Long-Term Users Need to Monitor Their B12 Levels
Data from the Diabetes Prevention Program show that about 1 in 5 people on long-term metformin developed low or borderline B12 after five years—roughly double the rate of the placebo group—and each additional year of use raises deficiency odds by approximately 13%. The catch: metformin-induced B12 deficiency can produce nerve damage that's easily misattributed to diabetic neuropathy, leading to undertreatment of the real cause. If you take metformin for longevity or metabolic health, annual B12 testing and supplementation deserve a serious look.
Read more →Research & Papers
18 Years of Rapamycin Data: Remove One Control Group and Its Lifespan Benefit Disappears
A close re-analysis of 18 years of ITP mouse data reveals that rapamycin's celebrated lifespan-extension result is sensitive to which control cohort is included—exclude one group, and the effect flips from extension to a trend toward reduction. This doesn't overturn the PEARL trial's human signals of muscle and mood benefits, but it is a serious methodological flag for anyone extrapolating ITP mouse data to personal rapamycin protocols. The field's most-cited aging intervention data deserves exactly this level of scrutiny.
Read more →Lowering Your Epigenetic Clock Score Doesn't Always Mean Better Health—A 26-Trial Review
A systematic review from Henan University screened 24,813 records and analyzed 26 human geroscience trials that measured both a DNA-methylation clock and a clinical outcome before and after treatment. The uncomfortable finding: reducing your epigenetic age does not reliably predict better clinical results across the board, raising real questions about whether biological age scores are true proxies for health or merely correlated markers. For anyone calibrating their supplement or lifestyle protocol around epigenetic clock data, this review is required reading.
Read more →Lifestyle & Nutrition
Bryan Johnson Adds Music to His Longevity Protocol—104 Randomized Trials Back Him Up
Bryan Johnson is calling music a 'longevity therapy,' citing a meta-analysis of 104 randomized controlled trials in 9,617 people showing that listening to a song you love lowers heart rate, blood pressure, cortisol, and anxiety. The protocol is disarmingly simple: put on a track you genuinely enjoy. Few longevity interventions combine this level of evidence with zero cost and zero side effects.
Read more →The 45-to-55 Window: Why Midlife Is the Highest-Leverage Moment to Fight Vascular Aging
A narrative review from Tongji University argues that the vascular system is a 'pioneer organ' that ages earlier than other systems and broadcasts aging signals throughout the body via the bloodstream. The authors, drawing on a 2025 protein atlas, identify the 45-to-55 age window as the highest-leverage period for intervention—before arterial stiffening and microvascular decline become self-reinforcing. If you're in this range, this is a compelling evidence-based case for aggressive cardiovascular risk management right now, not later.
Read more →Industry & Policy
First Human Administration of Senolytic Immunotherapy Marks a New Frontier in Aging Medicine
Immorta Bio has announced the first-ever human administration of a senolytic immunotherapy—a treatment designed to selectively eliminate senescent 'zombie' cells, which accumulate with age and drive chronic inflammation and organ decline. The therapy debuted in advanced cancer patients as an initial clinical proving ground, with expansion into broader aging diseases planned as the next step. Moving senolytics from decades of animal studies into human patients is a genuine milestone for the field.
Read more →